Search

Displaying results 641 - 650 of 10000 in total
  1. Drug

    Aluminum acetate

    go.drugbank.com/drugs/DB14518
    ApprovedInvestigational

    Products: ACETATO DE ALUMINIO 15 MG/100 ML SOLUCION TOPICA, ACETATO DE ALUMINIO 0.118G/100 ML
  2. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine lorazepam, is considered less susceptible to pharmacokinetic va...

    Products: Praxiten 15 mg - Tabletten, OXAZEPAM AL 10
  3. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.

    Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  4. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: REAMPLA 100 MG KAPSÜL, 7 KAPSÜL, REAMPLA 100 MG KAPSÜL, 21 KAPSÜL
  5. Drug

    Alprazolam

    go.drugbank.com/drugs/DB00404
    ApprovedIllicitInvestigational

    Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. … [L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.

    Synonyms: 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.

    Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
  7. Drug

    Celecoxib

    go.drugbank.com/drugs/DB00482
    ApprovedInvestigational

    Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other … [L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesProducts: Celecoxib 100 mg, SCHULLO 100 MG
  8. Drug

    Pholcodine

    go.drugbank.com/drugs/DB09209
    ApprovedIllicit

    [A31738] Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little or no analgesic effects. … [A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008.

    Products: DURO-TUSS REGULAR COUGH LIQUID 15 mg/15 ml, DHACODINE SYRUP 15 mg/5 ml
  9. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2.

    Mixtures: XIGDUO XR (TABLETS 10 MG/1000 MG), Qtern 5 mg/10 mg Film-Coated TabletsCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  10. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic IndexProducts: Fampridin STADA 10 mg Retardtabletten, Fampridin Sandoz 10 mg Retardtabletten